DK0867179T3 - Sammensætning af L-DOPA-estere - Google Patents

Sammensætning af L-DOPA-estere

Info

Publication number
DK0867179T3
DK0867179T3 DK98101741T DK98101741T DK0867179T3 DK 0867179 T3 DK0867179 T3 DK 0867179T3 DK 98101741 T DK98101741 T DK 98101741T DK 98101741 T DK98101741 T DK 98101741T DK 0867179 T3 DK0867179 T3 DK 0867179T3
Authority
DK
Denmark
Prior art keywords
composition
active ingredient
dopa
amount
pharmaceutically acceptable
Prior art date
Application number
DK98101741T
Other languages
Danish (da)
English (en)
Inventor
Isaac Milman
Daphne Atlas
Alexander Veinberg
Eldad Melamed
Original Assignee
Teva Pharma
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma, Yissum Res Dev Co filed Critical Teva Pharma
Application granted granted Critical
Publication of DK0867179T3 publication Critical patent/DK0867179T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Lubricants (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK98101741T 1992-12-24 1993-12-24 Sammensætning af L-DOPA-estere DK0867179T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/995,847 US5354885A (en) 1992-12-24 1992-12-24 Process for preparing ethyl ester of L-DOPA

Publications (1)

Publication Number Publication Date
DK0867179T3 true DK0867179T3 (da) 2000-11-06

Family

ID=25542272

Family Applications (2)

Application Number Title Priority Date Filing Date
DK93120894T DK0610595T3 (da) 1992-12-24 1993-12-24 Sammensætning af L-DOPA-estere
DK98101741T DK0867179T3 (da) 1992-12-24 1993-12-24 Sammensætning af L-DOPA-estere

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK93120894T DK0610595T3 (da) 1992-12-24 1993-12-24 Sammensætning af L-DOPA-estere

Country Status (21)

Country Link
US (2) US5354885A (de)
EP (2) EP0610595B1 (de)
JP (1) JPH07285860A (de)
CN (1) CN1083262C (de)
AT (2) ATE196081T1 (de)
AU (1) AU684053B2 (de)
CA (1) CA2112160A1 (de)
CY (1) CY2214B1 (de)
DE (2) DE69324466T2 (de)
DK (2) DK0610595T3 (de)
ES (2) ES2150294T3 (de)
FI (1) FI107994B (de)
GR (2) GR3030073T3 (de)
HK (1) HK1012577A1 (de)
HU (1) HU218906B (de)
IL (1) IL108147A (de)
LV (1) LV12766B (de)
NO (1) NO305932B1 (de)
NZ (1) NZ250541A (de)
PT (1) PT867179E (de)
ZA (1) ZA939573B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9203594D0 (sv) * 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US5840756A (en) * 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
AU7669496A (en) * 1995-11-03 1997-05-22 University Of Kentucky Method for the intranasal administration of l-dopa prodrugs
EP0866691B2 (de) * 1995-11-06 2005-01-26 Somerset Pharmaceuticals, Inc. Sublinguale und bukkale verabreichung von selegilin
AU768154B2 (en) * 1996-10-13 2003-12-04 Neuroderm Ltd Treatment of Parkinson's disease
US6746688B1 (en) 1996-10-13 2004-06-08 Neuroderm Ltd. Apparatus for the transdermal treatment of Parkinson's disease
IL119417A (en) * 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
US6166081A (en) * 1997-10-09 2000-12-26 Kushnir; Moshe Methods and apparatus for treatment of Parkinson's disease
ES2178405T3 (es) 1998-03-16 2002-12-16 Somerset Pharmaceuticals Inc Uso de selegilina o de desmetilselegilina para tratar heridas, quemaduras y lesiones cutaneas.
CN1325379A (zh) * 1998-11-10 2001-12-05 特瓦制药工业有限公司 L－dopa乙酯的制备方法
AU764742B2 (en) * 1998-11-10 2003-08-28 Teva Pharmaceutical Industries Ltd. Dispersible compositions containing L-DOPA ethyl ester
RU2157196C1 (ru) * 1999-06-17 2000-10-10 Васильев Виталий Николаевич Фармацевтическая композиция в.н. васильева для восстановления функции симпатико-адреналовой системы, способ оценки индивидуальной эффективности этой композиции для терапии пациентов
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6514482B1 (en) * 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
IL159813A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
US6696600B2 (en) * 2001-11-13 2004-02-24 Teva Pharmaceutical Industries, Ltd. L-DOPA ethyl ester salts and uses thereof
WO2003042136A2 (en) * 2001-11-13 2003-05-22 Teva Pharmaceutical Industries, Ltd. Process for the production of l-dopa ethyl ester
ES2487816T3 (es) 2002-03-20 2014-08-25 Civitas Therapeutics, Inc. Administración pulmonar de levodopa
US6930137B2 (en) * 2002-05-31 2005-08-16 Fina Technology, Inc. Method of improving blown film processing performance and physical properties
DE10261807A1 (de) * 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
WO2004069146A2 (en) * 2003-02-07 2004-08-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-dopa amide derivatives and uses thereof
CA2523567A1 (en) * 2003-04-25 2004-11-11 Indevus Pharmaceuticals, Inc. Method for promoting uninterrupted sleep by administration of trospium chloride
KR100525358B1 (ko) * 2003-08-21 2005-11-04 주식회사 이엔에프테크놀로지 카르복실 벤조트리아졸 알킬에스테르의 제조방법
MXPA06002344A (es) * 2003-08-29 2006-05-19 Transform Pharmaceuticals Inc Composiciones farmaceuticas y metodo para usar levodopa y carbidopa.
US8815950B2 (en) 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
CN1867359B (zh) * 2003-10-08 2010-12-15 马林克罗特公司 哌甲酯溶液及其制药用途和制备方法
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
CA2642593C (en) * 2006-02-17 2014-11-04 Birds Pharma Gmbh Berolina Innovative Research & Development Services Deuterated catecholamine derivatives and medicaments comprising said compounds
CN101623278B (zh) * 2008-07-09 2013-02-27 北京德众万全药物技术开发有限公司 一种含有左旋多巴和盐酸苄丝肼的药物组合物
AU2016258179B2 (en) 2015-05-06 2021-07-01 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
ES2764490T3 (es) * 2015-08-27 2020-06-03 Prexton Therapeutics Sa Derivado de oxima de cromona que penetra en el cerebro para la terapia de la discinesia inducida por levodopa
EP3518920A1 (de) 2016-09-29 2019-08-07 Berlirem GmbH L-dopa-derivate zur behandlung von neurologischen erkrankungen
HUE064010T2 (hu) 2021-02-09 2024-02-28 Biobab R&D S L A 3,4-dihidroxi-fenilalanin (dopa) enantiomerjeinek felhasználása a növények vonzerejének növelésére hasznos rovarok számára és az erre szolgáló eljárás

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA716958B (en) * 1970-10-30 1973-01-31 Hoffmann La Roche Phenylalanine amides
US3803120A (en) * 1971-09-28 1974-04-09 Hoffmann La Roche Di-and tripeptides of 3-(3,4-dihydroxyphenyl)-alanine
US3939253A (en) * 1973-11-02 1976-02-17 Interx Research Corporation Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease
JPS5157813A (en) * 1974-11-14 1976-05-20 Sankyo Co Ll dooba mataha sonojudotaiseizaino seiho
US4035507A (en) * 1975-04-17 1977-07-12 Interx Research Corporation Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease
US4916151A (en) * 1985-12-05 1990-04-10 Merrell Dow Pharmaceuticals Inc. Method of treating parkinson's syndrome
US4771073A (en) * 1985-12-30 1988-09-13 Merck & Co., Inc. Rectally absorbable form of L-dopa
US4663349A (en) * 1985-12-30 1987-05-05 Merck & Co., Inc. Rectally absorbable form of L-dopa
ES2042520T3 (es) * 1986-06-10 1993-12-16 Chiesi Farma Spa Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo.

Also Published As

Publication number Publication date
NO934768L (no) 1994-06-27
FI935847A (fi) 1994-06-25
EP0610595B1 (de) 1999-04-14
DE69329400T2 (de) 2001-01-18
NO305932B1 (no) 1999-08-23
DE69329400D1 (de) 2000-10-12
CN1083262C (zh) 2002-04-24
GR3034867T3 (en) 2001-02-28
AU5257793A (en) 1994-07-07
US5525631A (en) 1996-06-11
IL108147A (en) 1998-09-24
DK0610595T3 (da) 1999-10-25
FI107994B (fi) 2001-11-15
EP0610595A3 (en) 1994-09-21
ATE178793T1 (de) 1999-04-15
LV12766A (lv) 2001-12-20
EP0867179A1 (de) 1998-09-30
JPH07285860A (ja) 1995-10-31
NZ250541A (en) 1995-12-21
NO934768D0 (no) 1993-12-22
ES2132170T3 (es) 1999-08-16
CA2112160A1 (en) 1994-06-25
EP0867179B1 (de) 2000-09-06
ES2150294T3 (es) 2000-11-16
LV12766B (en) 2002-03-20
CN1094950A (zh) 1994-11-16
AU684053B2 (en) 1997-12-04
EP0610595A2 (de) 1994-08-17
CY2214B1 (en) 2002-11-08
FI935847A0 (fi) 1993-12-23
US5354885A (en) 1994-10-11
ZA939573B (en) 1994-08-11
DE69324466D1 (de) 1999-05-20
DE69324466T2 (de) 1999-11-25
IL108147A0 (en) 1994-04-12
GR3030073T3 (en) 1999-07-30
HUT68498A (en) 1995-06-28
HU218906B (hu) 2000-12-28
ATE196081T1 (de) 2000-09-15
HK1012577A1 (en) 1999-08-06
PT867179E (pt) 2000-12-29
HU9303748D0 (en) 1994-04-28

Similar Documents

Publication Publication Date Title
DK0867179T3 (da) Sammensætning af L-DOPA-estere
HUT59313A (en) Process for producing pharmaceutical composition comprising flupirtin as active ingredient and suitable for combatting muscular tensions
IL99699A0 (en) Method of treating or preventing type 1 diabetes by oral administration of insulin
IL133585A0 (en) Soluble prodrugs of paclitaxel
GR3019012T3 (en) Therapeutic compositions for intranasal administration which include ketorolac TM.
HUT47217A (en) Process for producing pharmaceutical compositions containing indol derivatives as active components
FI973163A (fi) Pidätyskyvyttömyyden hoitaminen käyttämällä (S)-oksibutyniiniä ja (S)-desetyylioksibutyniiniä
WO1999033450A3 (en) Pharmaceutical composition containing sibutramine and orlistat
HU9303000D0 (en) Aryl-morpholine-derivatives and pharmaceutical compositions containing it and process for production thereof
WO1993017691A3 (en) Pharmaceutical compositions containing monosialoganglioside gm1 or a derivative thereof suitable for the treatment of parkinson's disease
MY104521A (en) Treatment of depression.
BG106180A (en) Pharmaceutical composition containing sibutramine and orlistat
JPS57167922A (en) Psychotropic drug
SE9502877D0 (sv) Novel opioid peptides
RU97105771A (ru) Способ лечения сахарного диабета
MY110416A (en) Composition for the treatment of schizophrenia.
RU97113692A (ru) Применение 3,4-дифенилхроманов для получения фармацевтической композиции для лечения или профилактики церебральных дегенеративных расстройств